The Pharma Data

JANUARY 3, 2021

The information in the press release is information that Nanoform is obliged to make public pursuant to the EU Market Abuse Regulation. This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform’s strategy, business plans and focus. . +46 7686 650 11. 2 Proof of Concept.

Containment 52

Containment Bioavailability Clinical Trials Clinical Trials 52

The Pharma Data

NOVEMBER 26, 2020

The information in the press release is information that Nanoform is obliged to make public pursuant to the EU Market Abuse Regulation. This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform’s strategy, business plans and focus. Finnish time. About Nanoform.

Containment 52

Containment Medicine Bioavailability Clinical Trials 52

The Pharma Data

JANUARY 27, 2021

Each study is planned to be carried out over an approximately two-week period as an open label, randomized, crossover, two-period, two-sequence, single dose pilot study to assess the relative bioavailability of each product. About XPhyto Therapeutics Corp. XPhyto Therapeutics Corp.

Drugs 52

Drugs Manufacturing Drug Delivery Production 52

Pharmaceutical Technology

FEBRUARY 3, 2023

In 2021, 72% of newly approved drugs were small molecules, and almost 50% of new drugs approved were OSD. While the industry is seeing advances in alternative drug delivery systems, oral solid doses, such as pills, capsules and soft gels, remain at the forefront of the industry.

Contamination 130

Contamination Manufacturing Containment Production 130